drugset
drugset / Trial / NCT04644211

Ruxolitinib in Thrombocythemia and Polycythemia Vera

NCT04644211 ↗

Phase 2 Recruiting 60 enrolled Massachusetts General Hospital Incyte Corporation · collab
Non-randomizedSequentialOpen-labelTreatment

Summary

This research is being done to see if the drug ruxolitinib is effective in reducing the symptoms caused by low-risk essential thrombocythemia (ET) and polycythemia vera (PV). \- This research study involves the study drug Ruxolitinib.

Timeline

Start
2022-03-21
Primary completion
2027-07
Completion
2034-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Ruxolitinib Small molecule — Oral

Indications

acquired polycythemia vera essential thrombocythemia